ABC Arbitrage SA Acquires New Holdings in Genmab A/S (NASDAQ:GMAB)

ABC Arbitrage SA purchased a new stake in Genmab A/S (NASDAQ:GMAB) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 176,898 shares of the company’s stock, valued at approximately $3,692,000.

Other institutional investors have also recently modified their holdings of the company. Legacy Wealth Asset Management LLC grew its holdings in Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after acquiring an additional 471 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after purchasing an additional 827 shares during the period. GAMMA Investing LLC grew its holdings in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Eagle Asset Management Inc. grew its holdings in Genmab A/S by 10.0% in the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after purchasing an additional 1,121 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after purchasing an additional 1,413 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $21.30 on Friday. Genmab A/S has a one year low of $18.64 and a one year high of $31.88. The company has a market cap of $14.10 billion, a price-to-earnings ratio of 20.68, a PEG ratio of 0.54 and a beta of 0.96. The business’s 50 day moving average price is $20.66 and its 200 day moving average price is $23.20.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. On average, analysts predict that Genmab A/S will post 1.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on GMAB shares. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Finally, Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.